SA07280637B1 - مضادات أجسام مضادة للانقسام جديدة - Google Patents

مضادات أجسام مضادة للانقسام جديدة Download PDF

Info

Publication number
SA07280637B1
SA07280637B1 SA07280637A SA07280637A SA07280637B1 SA 07280637 B1 SA07280637 B1 SA 07280637B1 SA 07280637 A SA07280637 A SA 07280637A SA 07280637 A SA07280637 A SA 07280637A SA 07280637 B1 SA07280637 B1 SA 07280637B1
Authority
SA
Saudi Arabia
Prior art keywords
antibody
arrangement
cdr
defining
order
Prior art date
Application number
SA07280637A
Other languages
Arabic (ar)
English (en)
Inventor
كورفيا ناتلي
هاآو جون فرنسوا
بي سيدريك
جوتس ليليان
Original Assignee
بيير فابر ميديكامو
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by بيير فابر ميديكامو filed Critical بيير فابر ميديكامو
Publication of SA07280637B1 publication Critical patent/SA07280637B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SA07280637A 2006-11-24 2007-11-24 مضادات أجسام مضادة للانقسام جديدة SA07280637B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610329A FR2909092B1 (fr) 2006-11-24 2006-11-24 Nouveaux anticorps anti-proliferation

Publications (1)

Publication Number Publication Date
SA07280637B1 true SA07280637B1 (ar) 2012-04-11

Family

ID=37903981

Family Applications (1)

Application Number Title Priority Date Filing Date
SA07280637A SA07280637B1 (ar) 2006-11-24 2007-11-24 مضادات أجسام مضادة للانقسام جديدة

Country Status (27)

Country Link
US (2) US8071730B2 (enExample)
EP (1) EP2074148A1 (enExample)
JP (1) JP2010509931A (enExample)
KR (1) KR20090088878A (enExample)
CN (1) CN101535344B (enExample)
AU (1) AU2007324509B2 (enExample)
BR (1) BRPI0719323A2 (enExample)
CA (1) CA2670039A1 (enExample)
CL (1) CL2007003357A1 (enExample)
CR (1) CR10788A (enExample)
CU (1) CU23792A3 (enExample)
EC (1) ECSP099341A (enExample)
FR (1) FR2909092B1 (enExample)
GE (1) GEP20125629B (enExample)
GT (1) GT200900126A (enExample)
IL (1) IL198744A0 (enExample)
MA (1) MA30891B1 (enExample)
MX (1) MX2009005293A (enExample)
NI (1) NI200900079A (enExample)
NO (1) NO20092360L (enExample)
NZ (1) NZ576174A (enExample)
RU (1) RU2451689C2 (enExample)
SA (1) SA07280637B1 (enExample)
TN (1) TN2009000194A1 (enExample)
TW (1) TW200829602A (enExample)
UA (1) UA99602C2 (enExample)
WO (1) WO2008062063A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
CA2777698A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
CA2815277A1 (en) * 2010-10-29 2012-05-03 Immunogen, Inc. Novel egfr-binding molecules and immunoconjugates thereof
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130287790A1 (en) * 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
RU2756275C2 (ru) 2016-03-01 2021-09-29 Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. Антитела, специфические к рецептору полиовируса (pvr) человека
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
CA3032826A1 (en) * 2016-08-03 2018-02-08 Nextcure, Inc. Compositions and methods for modulating lair signal transduction
CN109022366A (zh) * 2018-08-16 2018-12-18 江南大学 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用
KR20220082007A (ko) 2019-10-08 2022-06-16 넥틴 테라퓨틱스 리미티드 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030171568A1 (en) * 1998-09-16 2003-09-11 Avi Ashkenazi Use of A33 antigens and JAM-IT
SK14812000A3 (sk) * 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
MXPA01009110A (es) * 1999-03-11 2002-08-20 Rmf Dictagene Sa Moleculas de adhesion vascular y modulacion de su funcion.
EP1708961B1 (en) * 2003-12-04 2011-03-09 Abbott Biotherapeutics Corp. Anti-ip-10 antibodies
WO2006008076A2 (en) * 2004-07-16 2006-01-26 Universita Degli Studi Di Milano Methods and agents stimulating the immune response
WO2006121207A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
EP2021371A2 (en) * 2006-04-28 2009-02-11 Oregon Health and Science University Monoclonal antibodies specific for pancreatic endocrine, exocrine or ductal cells

Also Published As

Publication number Publication date
NI200900079A (es) 2010-11-10
CA2670039A1 (en) 2008-05-29
AU2007324509B2 (en) 2013-01-17
TN2009000194A1 (en) 2010-10-18
KR20090088878A (ko) 2009-08-20
HK1132752A1 (en) 2010-03-05
CL2007003357A1 (es) 2008-04-04
CN101535344B (zh) 2013-10-16
MX2009005293A (es) 2009-08-07
AU2007324509A1 (en) 2008-05-29
GT200900126A (es) 2011-09-02
JP2010509931A (ja) 2010-04-02
GEP20125629B (en) 2012-09-10
RU2009123409A (ru) 2010-12-27
TW200829602A (en) 2008-07-16
US20100092455A1 (en) 2010-04-15
RU2451689C2 (ru) 2012-05-27
FR2909092B1 (fr) 2012-10-19
CR10788A (es) 2009-06-23
US8071730B2 (en) 2011-12-06
CU23792A3 (es) 2012-03-15
WO2008062063A1 (en) 2008-05-29
FR2909092A1 (fr) 2008-05-30
ECSP099341A (es) 2009-06-30
EP2074148A1 (en) 2009-07-01
MA30891B1 (fr) 2009-11-02
UA99602C2 (ru) 2012-09-10
CN101535344A (zh) 2009-09-16
NZ576174A (en) 2012-03-30
NO20092360L (no) 2009-08-11
US20120156191A1 (en) 2012-06-21
BRPI0719323A2 (pt) 2014-02-04
IL198744A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
JP7069261B2 (ja) Ｃｄ７３特異的結合分子及びその使用
US8071730B2 (en) Anti-JAM-A antibodies
KR102838340B1 (ko) 다중-특이적 항체 및 이들의 제조 및 사용 방법
CN113286634A (zh) 对gucy2c特异性的抗体及其用途
EP3988573A1 (en) Anti-cd3e/bcma bispecific antibody and use thereof
US12509520B2 (en) Anti-CD3 and anti-CD123 bispecific antibody and use thereof
JP2020536109A (ja) Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復
WO2018133842A1 (zh) 人程序性死亡受体pd-1的单克隆抗体及其片段
MX2012011234A (es) Anticuerpos contra csf-1r.
CN112955548A (zh) 叶酸受体α特异性抗体
JP7843824B2 (ja) 抗体および使用方法
CN114981301B (zh) Pd1和vegfr2双结合剂
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
CN114341170B (zh) 一种人源化抗vegfr2抗体及其应用
US12534518B2 (en) Fusion protein comprising anti-mesothelin antibody, anti-CD3 antibody or anti-EGFR antibody, bispecific or trispecific antibody comprising same, and uses thereof
IL321280A (en) Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof
JP7821544B2 (ja) 前立腺がんの診断及び早期発症に関して使用されるモノクローナル抗体
US20250289901A1 (en) Anti-cd3e/bcma bispecific antibody and use thereof
EP4620973A1 (en) Antibodies targeting cell surface deposited complement protein c3d and use thereof
JP2025516434A (ja) 抗ｃｄ７３抗体およびその使用
HK40105152A (en) Antibodies specific to muc18
CN120623343A (zh) 一种b7-h6单克隆抗体及其应用
HK40062048B (en) Antibody against claudin 18a2 and use thereof
HK40066232B (en) Humanized anti-vegfr2 antibody and application thereof
HK40060091A (en) Antibodies specific for gucy2c and uses thereof